New perspectives in medical management of hyperprolactinemia.
We performed 113 new treatments in 98 patients (pts) (69 females and 27 males), 41 with macroprolactinoma, 26 with microprolactinoma, 5 with empty sella and 26 with idiopathic hyperprolactinemia. Parlodel LA was administered in 31/113, Parlodel LAR in 51/113, Parlodel SRO in 24/113 and Cabergoline in 8/113. In each pt the clinical effect, PRL plasma level CT-scan and visual field examination were monitored. PRL plasma levels normalized in 84/98 pts. In 13/41 macroadenoma pts a complete disappearance of the adenomatous mass was observed at CT-scan after 0.5-3 years' oral bromocriptine or Parlodel LAR therapy. The clinical features normalized in most of the pts. In conclusion, the new long acting dopamine agonists may represent the future of the management of hyperprolactinemic states because of their effectiveness, tolerability and good compliance.
Montini
M
M
Department of Endocrinology, Neuroendocrine Unit, Bergamo, Italy.
Gianola
D
D
Pagani
M D
MD
Tengattini
F
F
Dominoni
P
P
Sileo
F
F
Ferrari
L
L
Stroppa
S
S
Gualteroni
L
L
Pagani
G
G
D000236:Adenoma / Q000188:drug therapy; D001971:Bromocriptine / Q000008:administration & dosage; D000077465:Cabergoline; D003692:Delayed-Action Preparations; D004652:Empty Sella Syndrome / Q000188:drug therapy; D004873:Ergolines / Q000627:therapeutic use; D005260:Female; D006801:Humans; D006966:Hyperprolactinemia / Q000188:drug therapy*; D008297:Male; D010911:Pituitary Neoplasms / Q000188:drug therapy
D003692:Delayed-Action Preparations; D004873:Ergolines; D001971:Bromocriptine; D000077465:Cabergoline